New diabetes drug SGL2 inhibitor -  Dapagliflozin

     New class of diabetes drug dapagliflozin from Bristol-Myers Squibb Co (BMY.N) and AstraZeneca PLC (AZN.L) reached the late-stage clinical trial. The drug, dapagliflozin, also led to statistically significant weight loss and a slight reduction in needed insulin dose, according to data presented at the American Diabetes Association scientific meeting in Orlando.

     Dapagliflozin belongs to a new class of oral Type 2 diabetes treatments called sodium-glucose transporter-2 inhibitors. Blocking the SGLT2 protein significantly increases the amount of glucose excreted in the urine that would otherwise be reabsorbed into the blood after passing through the kidneys.

     Researchers are of the opinion that SGLT2 inhibitors are advantageous across the spectrum of the diseases. Earlier successful Phase III studies tested dapagliflozin as a monotherapy and in combination with metformin, which is typically one of the first medicines doctors turn to in treating Type 2 diabetes.

New GLP-1 Oral Analogue.

     The new class of anti-diabetic drugs GLP-1 ( Glucagon Like Peptide-1 ) agonists from Zydus Cadila, a global healthcare provider and one of India's leading healthcare companies has received Phase I clinical trial permission from the DCGI.

     ZYOG1 would represent a next generation GLP-1 agent, the reason is that it need not be injected, but can be taken orally. ZYOG1, when administered by oral route demonstrated beneficial effects in preclinical models on glucose reduction, HbA1c reduction and showed an added benefit of weight loss. In addition, ZYOG1 has displayed a differentiated preclinical safety profile with no nausea-like symptoms in the preclinical studies.

Avandia in, but with hand cuffs for now!

.Read More